# SN BioScience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sn-bioscience

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.snbioscience.com
- Total disclosed funding: $16M
- Latest round: Series B (Jul 1, 2020)
- Investors on record: 13

## About

Founded in 2017 and based in Seoul, South Korea, SN Biosciecne utilizes double core-shell technology to research and develop its unique anticancer drug known as 'SN-38'.

## Funding rounds

- Series B, Jul 1, 2020, $6.7M — CKD Venture Capital, Bokwang Venture Capital, SL Investment, Daekyo Investment, Hana Securities, Widwin Investment, PCO Capital, JL Partners, Harang Invest
- Series B, Apr 14, 2020, $0.8M — WONIK Investment Partners
- Series B, Mar 28, 2020, $2.9M — Smilegate Investment, COMES Investment
- Series A, Jul 8, 2019, $6M — Smilegate Investment, OCI

## Investors

- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A, Series B
- OCI — Series A
- COMES Investment (https://capitalatlas.ai/funds/comes-investment) — Series B
- WONIK Investment Partners (https://capitalatlas.ai/funds/wonik-investment-partners) — Series B
- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series B
- Bokwang Venture Capital (https://capitalatlas.ai/funds/bokwang-venture-capital) — Series B
- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series B
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series B
- Hana Securities (https://capitalatlas.ai/funds/hana-securities) — Series B
- Widwin Investment (https://capitalatlas.ai/funds/widwin-investment) — Series B
- PCO Capital (https://capitalatlas.ai/funds/pco-capital) — Series B
- JL Partners (https://capitalatlas.ai/funds/jl-partners) — Series B
- Harang Invest (https://capitalatlas.ai/funds/harang-invest) — Series B